mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA based vaccine—individually tailored to target a patient's unique cancer mutations—was effective in a late stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer. The announcem...






